Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

ASP-1929 for the Treatment of Head and Neck Squamous Cell Carcinomas

Drug Name

ASP-1929

Developer

Rakuten Aspyrian

Therapy Class

Epidermal growth factor receptor antagonist

Product Description

Antibody drug conjugate of cetuximab and IRDye 700DX®

Current Indication

Head and neck squamous cell carcinomas

Market Sector

Oncology

Development Status

Phase three in progress
Expand
Close
Close
Close

Go Top